DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05501483

DiaSpax

RecruitingPhase NA

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

60

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Changes in fat cell lipolysis after 6 months of treatment

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05501483
Org study IDKarolinska University Hospital
Secondary ID2021-002367-21
Secondary ID2022-00792 and 2024-03434Swedish Research Council

Timeline

Milestones

Study first posted2022-08-15actual
Study start2023-02-08actual
Last update posted2025-02-26actual
Primary completion2026-09-01estimated
Study completion2032-12-31estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age30 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Signed informed consent
•BMI 25 kg/m2 or higher
•HbA1c 42 mmol/mol or higher
•For fertile women, effective contraception

Exclusion criteria

•HbA1c 65 mmol/mol or higher
•Established cardiovascular disease and/or heart failure
•Severe psychiatric condition
•Active alcoholism
•Insulin treatment
•Anticoagulant therapy (vitamin K antagonists or equivalent)
•Pregnancy, lactation
•Positive GAD or IA2 antibodies
•Low C-peptide/glucose ratio (less than 2 measured as pmol/mg per dL)
•NT-proBNP above the upper normal reference value
•Kidney disease
•Liver disease or hepatic values over twice the upper reference value
•Severe concomitant disease including ongoing cancer

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Cardiometabolic biomarkers
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Other/protocol endpoint/low confidence

Changes in tissue cellularity after 6 months of treatment (explorative outcome)

Time frame:Baseline and after six months intervention

change from baseline, descriptive

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Changes in fat cell heterogeneity after 6 months of treatment

Time frame:Baseline and after six months intervention

ratio, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Changes in fat cell lipolysis after 6 months of treatment

Time frame:Baseline and after six months intervention

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.